COGT
Cogent BiosciencesยทNASDAQ
--
--(--)
--
--(--)
COGT Profile
Cogent Biosciences, Inc.
A biotechnology company that focused on developing novel precision immunotherapies to treat cancer
275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451
--
Cogent Biosciences, Inc., was incorporated in March 2014 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on developing precision therapies for hereditary diseases. The company's approach is to design reasonable precision therapies that treat the root causes of disease and improve the lives of patients. The company's most advanced project is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to effectively inhibit KIT D816V mutations and other mutations in KIT exon 17.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
